Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway

Journal of Toxicological Sciences

Volumn 37, Issue 3, 2012, Pages 555-563

  Nakada, Tomohisa ^a   Kiyotani, Kazuma ^a   Iwano, Shunsuke ^a   Uno, Takahiko ^a   Yokohira, Masanao ^b   Yamakawa, Keiko ^b   Fujieda, Masaki ^a   Saito, Tetsuya ^a   Yamazak, Hiroshi ^a,c   Imaida, Katsumi ^b   Kamataki, Tetsuya ^a,c  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Lung cancer; Nicotine; P450 2A6; Tobacco smoking

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CASPASE; COTININE; CYTOCHROME P450 2A6; DOXORUBICIN; NICOTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MEDIATOR; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

MUS; NICOTIANA TABACUM;

EID: 84863110009     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.37.555     Document Type: Article

References (40)

1. Ariyoshi, N., Miyamoto, M., Umetsu, Y., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Nemoto, N., Sato, K. and Kamataki, T. (2002): Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev., 11, 890-894.
2. Benowitz, N.L. (1983): The use of biologic fluid samples in assessing tobacco smoke consumption. NIDA Res. Monogr., 48, 6-26.
3. Brognard, J., Clark, A.S., Ni, Y. and Dennis, P.A. (2001): Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 61, 3986-3997.
4. Carty, C.S., Huribal, M., Marsan, B.U., Ricotta, J.J. and Dryjski, M. (1997): Nicotine and its metabolite cotinine are mitogenic for human vascular smooth muscle cells. J. Vasc. Surg., 25, 682-688.
5. Dwoskin, L.P., Teng, L., Buxton, S.T. and Crooks, P.A. (1999): (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J. Pharmacol. Exp. Ther., 288, 905-911.
6. Fujieda, M., Yamazaki, H., Saito, T., Kiyotani, K., Gyamfi, M.A., Sakurai, M., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H. and Kamataki, T. (2004): Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis, 25, 2451-2458.
7. Fujita, K. and Kamataki, T. (2001): Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ. Mol. Mutagen., 38, 339-346.
8. Hecht, S.S. (1998): Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol., 11, 559-603.
9. Hecht, S.S. (1999): Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst., 91, 1194-1210.
10. Hecht, S.S. (2002): Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol., 3, 461-469.
11. Heeschen, C., Jang, J.J., Weis, M., Pathak, A., Kaji, S., Hu, R.S., Tsao, P.S., Johnson, F.L. and Cooke, J.P. (2001): Nicotine stimulates angiogenesis and promotes tumor growth and atherosclero-sis. Nat. Med., 7, 833-839.
12. Heeschen, C., Weis, M., Aicher, A., Dimmeler, S. and Cooke, J.P. (2002): A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest., 110, 527-536.
13. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009): Cancer statistics, 2009. CA Cancer J. Clin., 59, 225-249.
14. Jimenez, C., Jones, D.R., Rodriguez-Viciana, P., Gonzalez-Garcia, A., Leonardo, E., Wennstrom, S., von Kobbe, C., Toran, J.L., L, R.B., Calvo, V., Copin, S.G., Albar, J.P., Gaspar, M.L., Diez, E., Marcos, M.A., Downward, J., Martinez, A.C., Merida, I. and Carrera, A.C. (1998): Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J., 17, 743-753.
15. Jin, Z., Gao, F., Flagg, T. and Deng, X. (2004): Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J. Biol. Chem., 279, 23837-23844.
16. Kitagawa, K., Kunugita, N., Katoh, T., Yang, M. and Kawamoto, T. (1999): The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCRRFLP. Biochem. Biophys. Res. Commun., 262, 146-151.
17. Kushida, H., Fujita, K., Suzuki, A., Yamada, M., Endo, T., Nohmi, T. and Kamataki, T. (2000): Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis, 21, 1227-1232.
18. Klippel, A., Escobedo, M.A., Wachowicz, M.S., Apell, G., Brown, T.W., Giedlin, M.A., Kavanaugh, W.M. and Williams, L.T. (1998): Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell. Biol., 18, 5699-5711.
19. Le Marchand, L., Sivaraman, L., Pierce, L., Seifried, A., Lum, A., Wilkens, L.R. and Lau, A.F. (1998): Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res., 58, 4858-4863.
20. Mai, H., May, W.S., Gao, F., Jin, Z. and Deng, X. (2003): A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem., 278, 1886-1891.
21. Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., Nemoto, N., Sato, K., Ariyoshi, N. and Kamataki, T. (1999): CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun., 261, 658-660.
22. Miyazaki, M., Yamazaki, H., Takeuchi, H., Saoo, K., Yokohira, M., Masumura, K.I., Nohmi, T., Funae, Y., Imaida, K. and Kamataki, T. (2005): Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis, 26, 1947-1955.
23. Nagano, T., Shimizu, M., Kiyotani, K., Kamataki, T., Takano, R., Murayama, N., Shono, F. and Yamazaki, H. (2010): Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. Int. J. Environ. Res. Public Health., 7, 2953-2964.
24. Nakachi, K., Imai, K., Hayashi, S., Watanabe, J. and Kawajiri, K. (1991): Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res., 51, 5177-5180.
25. Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T. and Kuroiwa, Y. (1996a):. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos., 24, 1212-1217.
26. Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T. and Kuroiwa, Y. (1996b): Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther., 277, 1010-1015.
27. Newland, N., Baxter, A., Hewitt, K. and Minet, E. (2011): CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol. In Vitro, 25, 922-929.
28. Pianezza, M.L., Sellers, E.M. and Tyndale, R.F. (1998): Nicotine metabolism defect reduces smoking. Nature, 337, 750.
29. Plummer, H.K.3rd, Dhar, M. and Schuller, H.M. (2005): Expression of the α7 nicotinic acetylcholine receptor in human lung cells. Respir. Res., 6, 29.
30. Rehm, S., Ward, J.M. and Sass, B. (1994): Tumours of the lungs. IARC Sci. Publ., 325-355.
31. Song, N., Tan, W., Xing, D. and Lin, D. (2001): CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis, 22, 11-16.
32. Su, T., Bao, Z., Zhang, Q.Y., Smith, T.J., Hong, J.Y. and Ding, X. (2000): Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res., 60, 5074-5079.
33. Takeuchi, H., Saoo, K., Yokohira, M., Ikeda, M., Maeta, H., Miyazaki, M., Yamazaki, H., Kamataki, T. and Imaida, K. (2003): Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Res., 63, 7581-7583.
34. Tamaki, Y., Arai, T., Sugimura, H., Sasaki, T., Honda, M., Muroi, Y., Matsubara, Y., Kanno, S., Ishikawa, M., Hirasawa, N. and Hiratsuka, M. (2011): Association between cancer risk and drugmetabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab. Pharmacokinet., 26, 516-522.
35. Thorgeirsson, T.E., Gudbjartsson, D.F., Surakka, I., Vink, J.M., Amin, N., Geller, F., Sulem, P., Rafnar, T., Esko, T., Walter, S., Gieger, C., Rawal, R., Mangino, M., Prokopenko, I., Mägi, R., Keskitalo, K., Gudjonsdottir, I.H., Gretarsdottir, S., Stefansson, H., Thompson, J.R., Aulchenko, Y.S., Nelis, M., Aben, K.K., den Heijer, M., Dirksen, A., Ashraf, H., Soranzo, N., Valdes, A.M., Steves, C., Uitterlinden, A.G., Hofman, A., Tönjes, A., Kovacs, P., Hottenga, J.J., Willemsen, G., Vogelzangs, N., Döring, A., Dahmen, N., Nitz, B., Pergadia, M.L., Saez, B., De Diego, V., Lezcano, V., Garcia-Prats, M.D., Ripatti, S., Perola, M., Kettunen, J., Hartikainen, A.L., Pouta, A., Laitinen, J., Isohanni, M., Huei-Yi, S., Allen, M., Krestyaninova, M., Hall, A.S., Jones, G.T., van Rij, A.M., Mueller, T., Dieplinger, B., Haltmayer, M., Jonsson, S., Matthiasson, S.E., Oskarsson, H., Tyrfingsson, T., Kiemeney, L.A., Mayordomo, J.I., Lindholt, J.S., Pedersen, J.H., Franklin, W.A., Wolf, H., Montgomery, G.W., Heath, A.C., Martin, N.G., Madden, P.A., Giegling, I., Rujescu, D., Järvelin, M.R., Salomaa, V., Stumvoll, M., Spector, T.D., Wichmann, H.E., Metspalu, A., Samani, N.J., Penninx, B.W., Oostra, B.A., Boomsma, D.I., Tiemeier, H., van Duijn, C.M., Kaprio, J., Gulcher, J.R.; ENGAGE Consortium, McCarthy, M.I., Peltonen, L., Thorsteinsdottir, U. and Stefansson, K. (2010): Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet., 42, 448-453.
36. Tsao, A.S., McDonnell, T., Lam, S., Putnam, J.B., Bekele, N., Hong, W.K. and Kurie, J.M. (2003): Increased phospho-AKT (Ser(473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol. Biomarkers Prev., 12, 660-664.
37. Wang, H., Tan, W., Hao, B., Miao, X., Zhou, G., He, F. and Lin, D. (2003): Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobaccospecific carcinogen NNK. Cancer Res., 63, 8057-8061.
38. Xu, C., Rao, Y.S., Xu, B., Hoffmann, E., Jones, J., Sellers, E.M. and Tyndale, R.F. (2002): An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun., 290, 318-324.
39. Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., Takamiya, M., Aoki, Y. and Yokoi, T. (2005): CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos., 33, 1811-1818.
40. Yamazaki, H., Inoue, K., Hashimoto, M. and Shimada, T. (1999): Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol., 73, 65-70.